Biotech Is Back From The Dead

But health-care funds may cool off next quarter

What kind of company makes no money but promises fantastic growth, has a better chance of failure than success, and still lures investors? Hint: it's not dot-coms. That's right, biotech is back.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.